Cell Signaling Technology Logo - Extra Large
Trial Size Available Flag
Recombinant Flag
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

CD101/IgSF2 (F6H5E) Rabbit Monoclonal Antibody #46863

Filter:
  • WB

    Product Specifications

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 130
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    CD101/IgSF2 (F6H5E) Rabbit Monoclonal Antibody recognizes endogenous levels of total CD101/IgSF2 protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the extracellular domain of human CD101/IgSF2 protein.

    Background

    Cluster of differentiation molecule 101 (CD101), also known as immunoglobulin superfamily member 2 (IgSF2) and cell surface glycoprotein V7, is a type  I transmembrane glycoprotein with an extracellular region composed of seven IgV-like domains (1,2). CD101 is expressed on T cells, dendritic cells (DCs), and monocytes (3).  On T cells, CD101 expression is induced following T cell receptor (TCR) stimulation and plays an immunoregulatory role, inhibiting proliferation and IL-2 production by blocking Ca2+ flux and nuclear factor of activated T cells (NFAT) nuclear translocation (4). Regulatory T cells (Tregs) can express high levels of CD101 and are more suppressive than CD101- Tregs in in vitro suppression assays (5). CD101 is highly expressed on activated mucosal tissue-resident memory T cells and may play a role in balancing anti-inflammatory Tregs and pro-inflammatory Th17 cells in mucosal tissue (6). In CD8+ T cells, CD101 and TIM-3 expression defines a terminally differentiated state of exhaustion and dysfunction arising from chronic viral infection (7). In cutaneous DCs, triggering CD101 may lead to IL-10 production and the suppression of T cell proliferation (8). CD101 has been identified as a prognostic marker in glioma correlating with unfavorable overall survival and was found to be expressed at high levels on M2-like tumor-associated macrophages (TAMs) (9).

    Alternate Names

    CD101; CD101 molecule; Cell surface glycoprotein V7; EWI-101; EWI101; Glu-Trp-Ile EWI motif-containing protein 101; IGSF2; Immunoglobulin superfamily member 2; immunoglobulin superfamily, member 2; leukocyte surface protein; V7

    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.